Nutritional regulation of coupling factor 6, a novel vasoactive and proatherogenic peptide

- Coupling factor 6 (CF6) is released from endothelium and inhibits prostacyclin and nitric oxide generation by intracellular acidosis.
- High glucose elevates CF6, whereas CF6 causes diabetes, resulting in a vicious cycle.
- Low glucose increases inhibitory factor peptide 1, an endogenous inhibitor of CF6.
- High salt intake increases CF6, whereas CF6 induces salt-sensitive hypertension and salt-induced congestive heart failure.
- Vitamin C cancelled salt-induced increase in CF6, and estrogen leads to the delayed onset of hypertension and the rescue from cardiac systolic dysfunction.

High sodium, high glucose, and obesity are important risk factors for age-related diseases such as cardiovascular disease (CVDs), stroke, and cancer. Coupling factor 6 (CF6) is released from vascular endothelial cells and functions as a circulating peptide that inhibits prostacyclin and nitric oxide generation by intracellular acidosis. High glucose elevates CF6 by activation of protein kinase C and p38 mitogen-activated protein kinase, whereas CF6 causes type 2 diabetes mellitus, resulting in a high glucose vicious cycle. Low glucose increases inhibitory factor peptide 1, an endogenous inhibitor of CF6. High salt intake increases CF6 through nuclear factor κB signaling, whereas CF6 induces salt-sensitive hypertension and salt-induced congestive heart failure. Oral administration of vitamin C cancels salt-induced increase in CF6, and estrogen replacement leads to the delayed onset of CF6-induced salt-sensitive hypertension and the rescue from cardiac systolic dysfunction. Because CF6 contributes to the onset of CVDs, nutritional regulation of CF6 will shed light on the understanding of preventive strategy and mechanisms for CVDs and a target for therapy.